Re-Engagement of Patients with Hepatitis C in the Context of COVID-19

Abstract

Hepatitis C virus infection is one of the main causes of morbidity and mortality worldwide. In Argentina, it is estimated that only 50% of infected people are diagnosed; of these, half have confirmed their diagnosis, and only 5% have access to treatment.

The COVID-19 pandemic has exacerbated this situation, further decreasing access to treatment. In this context, we developed a program to reconnect and simplify the patient care cascade, in order to facilitate access to diagnosis, treatment, and monitoring of complications associated with hepatitis C virus infection.

24.2% of the re-engaged patients were candidates for treatment, and they received it in only 2 medical consultations, with an average time of 29 days between the initial consultation and the delivery of the medication. The results of our study show that approximately half of the patients with hepatitis C are not followed up by a specialist. Of the patients who had cirrhosis at the time of re-engagement, 60% had mild fibrosis prior to admission to the program. More than 80% of patients with cirrhosis could not be re-engaged. A commitment from the healthcare team is required to facilitate the reduction of the instances necessary to access treatment, and programs focused on education and assessment of the patient's psychosocial environment. This will make it possible to break down existing barriers.